Sugi Predict

Sugi Predict / Compounds / SCHEMBL267943

SCHEMBL267943

SCHEMBL267943

CCc1sc(N)c(C(=O)O)c1C

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 13/20 0.47
▸ MAPT P10636 9/20 0.47
▸ HPGD P15428 7/20 0.47
▸ ALOX15 P16050 2/20 0.47
▸ HSD17B10 Q99714 2/20 0.47
▸ NPSR1 Q6W5P4 2/20 0.47
▸ USP2 O75604 1/20 0.47
▸ RECQL P46063 1/20 0.47
▸ GAA P10253 5/20 0.44
▸ MEN1 O00255 3/20 0.44
▸ KMT2A Q03164 3/20 0.44
▸ LMNA P02545 2/20 0.44
▸ POLB P06746 1/20 0.44
▸ SMN1; SMN2 Q16637 1/20 0.44
▸ RAB9A P51151 2/20 0.42
▸ NPC1 O15118 1/20 0.42
▸ FHIT P49789 1/20 0.41
▸ MAPK1 P28482 1/20 0.40
▸ KDM4E B2RXH2 1/20 0.39
▸ GRM6 O15303 3/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8195991 0.83 ALDH1A1 (0.46) ALDH1A1MAPTHPGDALOX15HSD17B10
Hydrochloric Acid SCHEMBL28209357 0.83 ALDH1A1 (0.58) ALDH1A1MAPTHPGDALOX15HSD17B10
SCHEMBL10713707 0.81 ALDH1A1 (0.41) ALDH1A1MAPTHPGDALOX15HSD17B10
SCHEMBL22994585 0.80 ALDH1A1 (0.41) ALDH1A1MAPTHPGDALOX15HSD17B10
SCHEMBL10713052 0.80 ALDH1A1 (0.62) ALDH1A1MAPTHPGDALOX15HSD17B10
SCHEMBL10710308 0.80 ALDH1A1 (0.68) ALDH1A1MAPTHPGDALOX15HSD17B10
SCHEMBL23827438 0.80 MAPT (0.41) ALDH1A1MAPTHPGDALOX15HSD17B10
Water SCHEMBL11492577 0.79 MAPT (0.40) ALDH1A1MAPTHPGDALOX15HSD17B10
SCHEMBL8195949 0.77 ALDH1A1 (0.46) ALDH1A1MAPTHPGDALOX15HSD17B10
SCHEMBL27475039 0.77 ALDH1A1 (0.47) ALDH1A1MAPTHPGDALOX15HSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3515919-A1 N3-CYCLICALLY SUBSTITUTED THIENOURACILES AND USE THEREOF Bayer Aktiengesellschaft (DE) 2019-07-31 — — EP disclosed
EP-3274352-B1 HETEROCYCLYLMETHYL-THIENOURACILE AS ANTAGONISTS OF THE ADENOSINE-A2B-RECEPTOR Bayer Pharma AG (DE) 2019-01-02 — — EP disclosed
WO-2018054846-A1 N3-CYCLICALLY SUBSTITUTED THIENOURACILES AND USE THEREOF BAYER AKTIENGESELLSCHAFT (DE) 2018-03-29 — — WO disclosed
WO-2018041771-A1 (1-METHYLCYCLOPROPYL)METHYL-SUBSTITUTED THIENOURACILES AND USE THEREOF BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2018-03-08 — — WO disclosed
EP-3274352-A1 HETEROCYCLYLMETHYL-THIENOURACILE AS ANTAGONISTS OF THE ADENOSINE-A2B-RECEPTOR Bayer Pharma Aktiengesellschaft (DE) 2018-01-31 — — EP disclosed
EP-3055313-B1 CYCLIC THIENOURACIL CARBOXAMIDE AND ITS USE Bayer Pharma AG (DE) 2017-11-22 — — EP disclosed
WO-2016150901-A1 HETEROCYCLYLMETHYL-THIENOURACILE AS ANTAGONISTS OF THE ADENOSINE-A2B-RECEPTOR BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2016-09-29 — — WO disclosed
EP-3055313-A1 CYCLIC THIENOURACIL-CARBOXAMIDES AND USE THEREOF Bayer Pharma Aktiengesellschaft (DE) 2016-08-17 — — EP disclosed
WO-2015052065-A1 CYCLIC THIENOURACIL-CARBOXAMIDES AND USE THEREOF BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2015-04-16 — — WO disclosed
US-20120115851-A1 COMPOUND INHIBITING IN VIVO PHOSPHORUS TRANSPORT AND MEDICINE CONTAINING THE SAME KYOWA HAKKO KIRIN CO., LTD. (JP) 2012-05-10 — — US disclosed
US-8134015-B2 Compound inhibiting in vivo phosphorous transport and medicine containing the same KYOWA HAKKO KIRIN CO., LTD. (JP) 2012-03-13 — — US disclosed
WO-2008063668-A1 HETEROBICYCLIC METALLOPROTEASE INHIBITORS ALANTOS PHARMACEUTICALS HOLDING, INC. (US) 2008-05-29 — — WO disclosed
US-20070208040-A1 e.g. 3-ethyl-5-methyl-1,3-dihydrothiopheno[2,3-d]pyrimidine-2,4-dione; neurodegenerative disorders, antiischemic agent, antidepressant, attention deficit disorder, hepatic fibrosis, cirrhosis of the liver, and drug addiction GILEAD PALO ALTO, INC. 2007-09-06 — — US disclosed
US-20060217426-A1 Compound inhibiting in vivo phosphorous transport and medicine containing the same KIRIN BEER KABUSHIKI KAISHA (JP) 2006-09-28 — — US disclosed
EP-1614676-A1 COMPOUND INHIBITING IN VIVO PHOSPHORUS TRANSPORT AND MEDICINE CONTAINING THE SAME KIRIN BEER KABUSHIKI KAISHA (JP) 2006-01-11 — — EP disclosed
US-20050124667-A1 Oxamide inhibitors of plasminogen activator inhibitor-1 CEREP SA (FR) 2005-06-09 — — US disclosed
US-4692461-A PLANT PROTECTION BAYER AKTIENGESELLSCHAFT (DE) 1987-09-08 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060217426-A1 Compound inhibiting in vivo phosphorous transport and medicine containing the same SLC10A6, SLC7A1, SLC10A1 ALDH1A1 3022/4885MAPT 4195/4885HPGD 2509/4885
US-20050124667-A1 Oxamide inhibitors of plasminogen activator inhibitor-1 SERPINE1, SERPINC1, SERPINB1 ALDH1A1 360/4885MAPT 4191/4885HPGD 655/4885
US-20070208040-A1 e.g. 3-ethyl-5-methyl-1,3-dihydrothiopheno[2,3-d]pyrimidine-2,4-dione; neurodegenerative disorders, antiischemic agent, antidepressant, attention deficit disorder, hepatic fibrosis, cirrhosis of the liver, and drug addiction CHRNE, CHRNA3, CHRNA1 ALDH1A1 419/4885MAPT 403/4885HPGD 1423/4885
US-20120115851-A1 COMPOUND INHIBITING IN VIVO PHOSPHORUS TRANSPORT AND MEDICINE CONTAINING THE SAME SLC34A1, SLC34A2, SLC20A2 ALDH1A1 2872/4885MAPT 4648/4885HPGD 2407/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.